Le Lézard
Classified in: Health
Subjects: ACC, MAT

KALY- Kali-Extracts Anticipates Gross Margin Increase from Cannabis Biopharmaceutical Technology Consolidation


DALLAS, Jan. 27, 2020 /PRNewswire/ -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) ("KALY") today announced an anticipated increase in gross margins from the consolidation of its business structure and focus on its Cannabis Biopharmaceutical Technology.  KALY has a U.S. Patented Cannabis Extraction Process and is developing treatments for various medical conditions.  The technology has been valued at $50 million in conjunction with a recent acquisition offer that KALY management passed on. The consolidation strategy includes plans to spin off its agricultural CBD extractions business and CBD confections business. KALY has entered into discussions with Puration, Inc. (USOTC: PURA) ("PURA") regarding PURA's possible acquisition of KALY's CBD confection assets. KALY has also announced entering negotiations with a third-party regarding the spinoff of the agricultural CBD extraction business. The third-party is not yet disclosed, but the party is a public company and a term sheet agreement is anticipated within the next two weeks.  The two spinoffs include plans for KALY to receive royalties from the ongoing extraction and confections business operations as part of the consideration for the assets.  The royalty revenue as designed in the spinoff structure would be a higher gross margin revenue than the current operating revenue.

Follow further developments at
https://www.kali-extracts.com/

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and as such, may involve risks and uncertainties. These forward looking statements relate to, amongst other things, current expectation of the business environment in which the company operates, potential future performance, projections of future performance and the perceived opportunities in the market. The company's actual performance, results and achievements may differ materially from the expressed or implied in such forward-looking statements as a result of a wide range of factors.

CONTACT:
Frederick Ferri
[email protected]
+1(214)210-0459

 

SOURCE Kali-Extracts, Inc.


These press releases may also interest you

at 16:35
Geron Corporation , a late-stage clinical biopharmaceutical company, today announced that it will release its first quarter 2024 financial results and business highlights before the market opens on Thursday, May 2, 2024 via press release, which will...

at 16:35
Tilray Brands, Inc. , a leader in the craft beer and cannabis-lifestyle industries, celebrates high honors and awards at the 2024 Craft Brewer's Conference and World Beer Cup. 10 Barrel Brewing won four craft beer awards and 10...

at 16:34
Fusion Pharmaceuticals Inc. , a clinical-stage oncology company focused on developing next-generation radioconjucates (RCs) as precision medicines, today announced that it has filed and is in the process of mailing the management information circular...

at 16:30
In an important step toward driving long-term affordability and access to treatments for chronic and complex conditions, Evernorth Health Services announced that it will have a Humira® biosimilar available for $0 out of pocket for eligible...

at 16:28
Dr. Siva Mohan, Co-Founder and Chief Medical Officer of RazorMetrics, an Austin-based drug cost reduction platform, is the Best Entrepreneur - Health Products & Services Status: Silver Stevie Winner from the American Business Awards. The Stevie®...

at 16:20
The Board of Directors of Revvity , today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 9, 2024 to all shareholders of record at the close of business on July 19, 2024. About Revvity ...



News published on and distributed by: